Shots:

• The P-IIb/III trial evaluates KSI-301 vs aflibercept (q8w) in 559 treatment-naïve patients with neovascular AMD
• The study did not meet the 1EPs of non-inferior visual acuity gains in patients dosed on extended regimens, strong durability, was safe & well tolerated with no new safety signals. In a pre-specified secondary analysis, 59% of patients achieved 5mos. dosing @1yr. with visual acuity gains & anatomic improvements over aflibercept
• KSI-301 is being studied at 150+ study sites in 10+ countries. The results from the P-III (GLEAM) and (GLIMMER) for DME along with (DAYLIGHT) study for wet AMD are expected in early 2023

 Ref: PR Newswire | Image: Stock Light